Premature ejaculation

Signati™ Medical, Inc. Announces Board Member Dr. Jones Joins Urology Austin

Retrieved on: 
Monday, February 12, 2024
Erectile dysfunction, Infertility, Leroy Jones, Male, Urinary incontinence, Urology, Premature ejaculation, Microsurgery, Medicine, MD

Providence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin.

Key Points: 
  • Providence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin.
  • Dr. Jones has been on the leading edge of men’s sexual health and prosthetic surgery for decades.
  • As an industry leader in prosthetic surgery, Dr. Jones has performed more than 3,500 penile implants and artificial urinary sphincter procedures.
  • He specializes in erectile dysfunction, erectile growth enhancement, Peyronies Disease, low testosterone, premature ejaculation, urinary incontinence, and male infertility — vasectomies, reversals, and microsurgery.

Global Premature Ejaculation Therapeutics Market Insights Report 2024-2029 Featuring Prominent Vendors - Plethora Solutions, Pfizer, Eli Lilly and Co, GSK, Menarini - ResearchAndMarkets.com

Retrieved on: 
Monday, December 11, 2023
Health, Pharmaceutical, Sale, Prevalence, Therapy, Ageing, GSK plc, Premature ejaculation, Route of administration, GSK, ROA, Eli Lilly and Company, Growth, Menarini, Administration, Physician, Selective serotonin reuptake inhibitor, Pharmaceutical industry, Generic drug, Pfizer

This report offers market size & forecast data for the global premature ejaculation therapeutics market.

Key Points: 
  • This report offers market size & forecast data for the global premature ejaculation therapeutics market.
  • This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029.
  • Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market.

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Retrieved on: 
Thursday, November 16, 2023
Pharmacokinetics, Contract research organization, US Foods, IND, MHRA, Clinical trial, Premature ejaculation, Patient, FDA, Investigational New Drug, Male, Human, Health care, CTA, Safety, Pharmaceutical industry, Atlantic Ocean

KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation.

Key Points: 
  • KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation.
  • These regulatory approvals signify a potential breakthrough in the management of a widespread condition, impacting up to 20% of men and their partners worldwide.
  • The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO).
  • Dr Ryan Protzko, Kanna Health's President, stated: "Our clinical trial approval on both sides of the Atlantic represents a critical milestone as we officially become a clinical stage company.

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Retrieved on: 
Thursday, November 16, 2023
Pharmacokinetics, Contract research organization, US Foods, IND, MHRA, Clinical trial, Premature ejaculation, Patient, FDA, Investigational New Drug, Male, Human, Health care, CTA, Safety, Pharmaceutical industry, Atlantic Ocean

KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation.

Key Points: 
  • KH-001 is a unique, proprietary on-demand drug being developed as the first FDA-approved treatment for premature ejaculation.
  • These regulatory approvals signify a potential breakthrough in the management of a widespread condition, impacting up to 20% of men and their partners worldwide.
  • The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO).
  • Dr Ryan Protzko, Kanna Health's President, stated: "Our clinical trial approval on both sides of the Atlantic represents a critical milestone as we officially become a clinical stage company.

Promescent Expands Distribution to 3,900 US-Based Walmart Locations

Retrieved on: 
Monday, September 25, 2023
Science, Premature ejaculation, Partnership, Research, MD, Collection, Birth control, Grocery store, Nursing, Walmart

LAS VEGAS, Sept. 25, 2023 /PRNewswire/ -- Promescent, a sexual wellness company specializing in a comprehensive range of science-backed products, announced today that it has expanded distribution of its bestselling Delay Spray, a clinically-proven lidocaine desensitizing spray, to all 3,900 Walmart locations nationwide.

Key Points: 
  • "At Promescent, we're committed to empowering individuals and couples to achieve a fulfilling sex life," says Promescent CEO Jeff Abraham.
  • "Expanding in Walmart has been an instrumental part of our retail strategy to make our science-backed products widely accessible to those who need it.
  • We're honored to grow our partnership with Walmart and bring our bestselling Delay Spray to a bigger community of discerning consumers nationwide."
  • Promescent's bestselling Delay Spray was previously available in 1,000 Walmart locations, but will be available in the family planning planogram in all US-based Walmart stores by early October.

Sex Should Be Fun, Not Stressful. Male Plus Can Help

Retrieved on: 
Friday, June 30, 2023
Blood vessel disorder, Cleveland Clinic, Ginseng, Premature ejaculation, Psychological abuse, Plasma protein binding, Male, Testosterone, Tribulus terrestris, Erectile dysfunction, Smoking, Birth control, Lepidium meyenii

Fort Lauderdale, FL, June 30, 2023 (GLOBE NEWSWIRE) -- Male Plus is a natural libido enhancer created by Belgian fitness entrepreneur Tim Torfs.

Key Points: 
  • Fort Lauderdale, FL, June 30, 2023 (GLOBE NEWSWIRE) -- Male Plus is a natural libido enhancer created by Belgian fitness entrepreneur Tim Torfs.
  • “Male Plus was created with one mission in mind,” says Torfs, “to restore an active, fun, and fulfilling sex life for those struggling in the bedroom.
  • But there are many other reasons men can struggle to enjoy their sex life.
  • The result is a slow, difficult, or even non-existent sex life, which is something Torfs finds unacceptable and counterproductive.

Urologists Explore Online Educational Content, Erectile Dysfunction Drug Choices and Physical Therapy to Treat Premature Ejaculation

Retrieved on: 
Friday, April 28, 2023
Online, Systematic review, Abstract, LPE, Interview, Penis, Storey, Communication, Premature ejaculation, Case Western Reserve University School of Medicine, American Urological Association, Rehabilitation, Meta-analysis, Stanford University Medical Center, Assistant, PFM, MD, Sapienza University of Rome, Ejaculation, Coronary artery disease, Erectile dysfunction, Vita-Salute San Raffaele University, Birth control, Urology

Are there meaningful differences in drug choice for men with coronary artery disease and erectile dysfunction?

Key Points: 
  • Are there meaningful differences in drug choice for men with coronary artery disease and erectile dysfunction?
  • Researchers will be presenting these sexual health study findings at the 118th Annual Scientific Meeting of the American Urological Association.
  • "Long term follow-up outcomes of pelvic floor rehabilitation in subjects suffering from lifelong premature ejaculation: retrospective multicentre study."
  • Highlights include a study showing commonly prescribed erectile dysfunction treatments reduce life-threatening cardiovascular diseases, and another study utilizing physical therapy to treat premature ejaculation," said Dr. Bajic.

Study Shows: Steady Freddy Can Help American Men Last Longer in Bed

Retrieved on: 
Tuesday, April 18, 2023
Anxiety, LAS, Premature ejaculation, Human, Clinical trial, Ejaculation, American Journal, Lidocaine, International Society, Sensation, American Journal of Men's Health, Frustration, Birth control

LAS VEGAS, April 18, 2023 /PRNewswire/ -- Steady Freddy – an innovator in safe and effective sexual health solutions – today announced the publication of a study in the peer-reviewed American Journal of Men's Health. The study demonstrates the clinical effectiveness of Steady Freddy Delay Spray on premature ejaculation with impressive results of significant improvement in sexual satisfaction.

Key Points: 
  • The study demonstrates the clinical effectiveness of Steady Freddy Delay Spray on premature ejaculation with impressive results of significant improvement in sexual satisfaction.
  • Over 12 weeks, 150 participants in the clinical trial received either a placebo or Steady Freddy Delay Spray.
  • Overall, Steady Freddy Delay Spray helped men last longer, boost confidence levels, and drive confidence in their ability to perform in the bedroom.
  • "We know that Steady Freddy is an effective solution for delaying ejaculation and the results of this study reflect this," said Dr. David Reiner, Founder and Chief Medical Officer of Steady Freddy .

Endurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in China

Retrieved on: 
Monday, April 17, 2023
Male, PE, Health, Pharmacy, Intra, New Drug Application, Premature ejaculation, NDA, Fosun International, Sale, IPE, Hospital, Patient, European, National Medical Products Administration, Ageing, IELT, NMPA, Fine chemical, Lidocaine/prilocaine, PRC

Compared to both baseline and placebo, Senstend(TM) produced clinically and statistically significant increases in IELT, ejaculatory control and satisfaction and reduction in distress.

Key Points: 
  • Compared to both baseline and placebo, Senstend(TM) produced clinically and statistically significant increases in IELT, ejaculatory control and satisfaction and reduction in distress.
  • Jamie Gibson, CEO of the Group, said, "We are delighted with the highly significant and positive results from the Phase 3 clinical study in China, which reinforces the results from the European and US Phase 3 clinical studies.
  • All costs of the clinical trials, including any other associated regulatory and submission costs for Senstend(TM) are covered by Wanbang Biopharmaceutical.
  • The Company reports positive results in certain countries in the European Union, where Fortacin(TM) has returned to the market.

What Does Ginseng Have to Do With Libido?

Retrieved on: 
Wednesday, April 5, 2023
Tribulus terrestris, Blood, Premature ejaculation, Tissue, Male, Nitric oxide, System, Depression, Oxidative stress, ED, Libido, Dietary supplement

Premature ejaculation, excessive alcohol consumption, and depression (many of which are lumped under the umbrella term “erectile dysfunction” or ED) can all exacerbate poor libido.

Key Points: 
  • Premature ejaculation, excessive alcohol consumption, and depression (many of which are lumped under the umbrella term “erectile dysfunction” or ED) can all exacerbate poor libido.
  • The creator of the natural libido-enhancing supplement Male Plus has worked as both a male beautician and fitness coach.
  • Beyond that, Ginseng is present in the Male Plus formula to boost energy, calm the body, and destress the mind.
  • “While Tribulus Terrestris and Maca Root are there to help with function, Ginseng sets the stage,” explains Torfs, “It’s an important step.